Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (321-330 of 426) with videos related to

Pageof 43
Sort By:
JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 31, 2023
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate CancerAntje Neeb, Ines Figueiredo, Bora Gurel, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
The Journal of Clinical Investigation|October 19, 2018
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerAdam Sharp, Ilsa Coleman, Wei Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|October 31, 2025
International expert consensus on the clinical integration of circulating tumor cells in solid tumorsEleonora Nicolò, Carolina Reduzzi, Jean-Yves Pierga, et al.
The Lancet. Oncology|July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialShahneen K Sandhu, William R Schelman, George Wilding, et al.
European Urology Oncology|June 26, 2024
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort DEvan Y Yu, Cristiano Ferrario, Mark D Linch, et al.
Cancers|June 2, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsRebeca Lozano, David Lorente, Isabel M Aragon, et al.
Cell|June 16, 2018
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate CancerYi-Mi Wu, Marcin Cieślik, Robert J Lonigro, et al.
Pageof 43

Showing results (321-330 of 426) with videos related to

Sort By:
Pageof 43
JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 31, 2023
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate CancerAntje Neeb, Ines Figueiredo, Bora Gurel, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
The Journal of Clinical Investigation|October 19, 2018
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerAdam Sharp, Ilsa Coleman, Wei Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|October 31, 2025
International expert consensus on the clinical integration of circulating tumor cells in solid tumorsEleonora Nicolò, Carolina Reduzzi, Jean-Yves Pierga, et al.
The Lancet. Oncology|July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialShahneen K Sandhu, William R Schelman, George Wilding, et al.
European Urology Oncology|June 26, 2024
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort DEvan Y Yu, Cristiano Ferrario, Mark D Linch, et al.
Cancers|June 2, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsRebeca Lozano, David Lorente, Isabel M Aragon, et al.
Cell|June 16, 2018
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate CancerYi-Mi Wu, Marcin Cieślik, Robert J Lonigro, et al.
Pageof 43